Antimicrobial Stewardship is complex
Renewed attention is being focused on the importance of antimicrobial stewardship in reducing the development of antimicrobial resistance. Recent regulatory changes provide meaningful impetus for health-system pharmacists to evaluate the effectiveness of their antimicrobial stewardship (AMS) program. These regulatory changes include:
- Updated Joint Commission medication management standards on antimicrobial stewardship in 2023, and
- New requirements on Antimicrobial Use and Resistance (AUR) reporting to the National Healthcare Safety Network (NHSN) to satisfy the Public Health and Clinical Data Exchange objective of the Medicare Promoting Interoperability program in 2024.
In this article series, we aim to deliver concise, practical, and actionable items as a resource to busy clinicians to help them assess their AMS programs, identify opportunities for improvement, and succeed in meeting any accreditation and regulatory requirements.